Gregg Klang, Femtech founder of CERN Corporation, discusses the development of a microbiocidal light device for yeast and bacterial vaginosis treatment. The device offers an alternative to drug-based therapies, catering to those who prefer non-medication options. Greg explains the status of development, including human trials, in vitro and ex vivo testing, and animal testing for safety. Tune in to learn more about his journey into women's health tech innovation with CERN Corporation.
Timestamps
- (01:20) CERN Corporation was founded to develop a non-drug therapy for yeast and bacterial vaginosis, targeting those for whom drug-based therapies are not effective or desired.
- (10:23) The CERN device uses microbiocidal light therapy to target key pathogens associated with yeast and bacterial vaginosis, providing a non-drug treatment option.
- (16:39) The CERN device is designed to accommodate different sizes to ensure comfort and effectiveness for women with varying pelvic floor conditions, including hypertonicity.
- (32:26) Physicians are impressed by the CERN device's approach and potential benefits for patients, expressing interest in its availability and integration into their practices.
- (44:24) The founder of CERN Corporation emphasizes the importance of the team's support and expertise in driving the development and success of the non-drug therapy device.
Host Bio
This podcast is hosted by Sheree Dibiase, PT ICLM. She is a nationally recognized women's health physical therapist who owns seven private clinics — one of the biggest networks in the US. She has spent 30+ years practicing in the oncology, pelvic floor, and prenatal postpartum healthcare spaces. She was also a professor for seven years a Loma Linda University where she taught kinesiology.
Brought to you by...
Keywords
Femtech, Women's Health, Pelvic Floor, Breast Cancer, Prenatal & postpartum